Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306878 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00306878 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 45 participants.
The verdict
NCT00306878, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)
Interventions
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1995-08 |
| Est. Completion | 1997-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306878
The ClinicalTrials.gov registry entry for NCT00306878 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abatacept is the first listed.
NCT00306878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306878 about?
NCT00306878 is a clinical study titled "Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris". The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)
What is the current status of trial NCT00306878?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 1995-08. Estimated completion is 1997-05.
What interventions are being tested in trial NCT00306878?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT00306878?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.